Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery

Nature Reviews Clinical Oncology

Volumn 12, Issue 1, 2015, Pages 10-

  Gao, Qiang ^a   Wang, Xiao Ying ^a   Zhou, Jian ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER RESECTION; MEDICAL DECISION MAKING; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 84927174151     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.122-c1     Document Type: Letter

References (15)

1. Forner, A., Gilabert, M., Bruix, J. &Raoul, J. L. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 11, 525-535 (2014).
2. Ho, E. Y. et al. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford) 16, 758-767 (2014).
3. Yau, T. et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146, 1691-1700 (2014).
4. European Association for the Study of the Liver &European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
5. Bruix, J., Gores, G. J. &Mazzaferro, V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844-855 (2014).
6. Zhong, J. H., Wu, F. X. &Li, H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol. 35, 8355-8358 (2014).
7. Han, K. H. et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 81 (Suppl. 1), 158-164 (2011).
8. Kudo, M. et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 29, 339-364 (2011).
9. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology; NCCN guidelines for treatment of cancer by site [online], http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site (2014).
10. Yin, L. et al. Partial hepatectomy vs. Transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J. Hepatol. 61, 82-88 (2014).
11. Cucchetti, A. et al. When to perform hepatic resection for intermediate stage hepatocellular carcinoma. Hepatology http://dx.doi.org/10.1002/hep.27321 (2014).
12. Bolondi, L. et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin. Liver Dis. 32, 348-359 (2012).
13. Piscaglia, F. et al. Clinical validation of a sub-staging proposal of patients with intermediate HCC (BCLC-B). J. Hepatol. 58, S48-S49 (2013).
14. Ha, Y. et al. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J. Gastroenterol. Hepatol. 29, 787-793 (2014).
15. Vennarecci, G. et al. The ALPPS procedure for hepatocellular carcinoma. Eur. J. Surg. Oncol. 40, 982-988 (2014).